Zloza Laboratory


Zloza Laboratory

     Research Overview

     Andrew Zloza, MD, PhD

     Current Lab Members

     Lab Alumni

Research Overview

Our laboratory focuses on understanding the interplay between infections, cancer, and the immune system. We have discovered that non-oncogenic infections (those that do not directly cause cancer) regulate tumor occurrence and growth (in both negative and positive ways). Therefore, we strive to understand the mechanism underlying these effects and to translate our findings toward patient therapies against cancer.

News and Events

APRIL 2017

AWARD + FUNDING: Thanks to the organizers of the 3rd Annual Immuno-Oncology Young Investigators’ Forum and to the Faculty Judges for my 2nd Place Award and Research Grant in the Junior Faculty Category! It was completely unexpected but is greatly appreciated!

PUBLICATION: Thanks to the Gupta Lab (Rush University) for including us on this study "CD11b activation suppresses TLR-dependent inflammation and autoimmunity in systemic lupus erythematosus" published in Journal of Clinical Investigation!


MARCH 2017 

PUBLICATION: Thanks to our friends at Oncoceutics and internal collaborators (Rutgers CINJ) for including us on this study "First-in-Human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors" published in Clinical Cancer Research!



PUBLICATION: Thanks to the Reiser Lab (Rush University) for including us on this study "Bone marrow-derived immature myeloid cells are a main source of circulating suPAR contributing to proteinuric kidney disease" published in Nature Medicine!



PUBLICATION: Thanks to the Lasfar Lab (Rutgers) for including us on this study "IFN-λ: A New Inducer of Local Immunity against Cancer and Infections" published in Frontiers in Immunology.



PUBLICATION: Our study “Non-oncogenic acute viral infections disrupt anti-cancer responses and lead to accelerated cancer-specific host death” is now published in Cell Reports!



FUNDING: Congrats to the Zloza Laboratory on the funding of their study “Autologous double-humanized mouse model for the study of Pembrolizumab” (MISP # 55542) by Merck Sharp & Dohme Corp (PI: Zloza). 

FUNDING: The Zloza Laboratory has been awarded research funding from Gateway For Cancer Research for their proposed collaborative work with the Kaufman Lab (Rutgers) on the study “Combination Oncolytic Virus and PD-1 Blockade for Melanoma Treatment” (PI: Kaufman, Co-I: Zloza)

PUBLICATION: “Low dose interleukin-2 (IL-2) impairs host anti-tumor immunity and inhibits therapeutic responses” in Cancer Immunology, Immunotherapy in collaboration with the Kaufman Laboratory at Rutgers CINJ.



PUBLICATION: Thanks to the Lasfar Lab (Rutgers) for including us on the review "Concerted action of IFN-α and IFN-λ induces local NK cell immunity and halts cancer growth" published in Oncotarget!



PUBLICATION: Thanks to the Lasfar Lab (Rutgers) for including us on the reivew "IFN-lambda therapy: current status and future perspectives" published in Drug Discovery Today!



PUBLICATION: Thanks to the Kaufman Lab (Rutgers CINJ) for including us on the reivew "Talimogene laherparepvec (T-VEC) as cancer immunotherapy" published in Drugs Today!

PUBLICATION: Our review "Oncolytic viruses: a new class of immunotherapy drugs" has been published in Nature Reviews Drug Discovery!


MAY 2015

PUBLICATION: Our study "NK cells and CD8+ T cells cooperate to improve therapeutic responses in melanoma treated with interleukin-2 (IL-2) and CTLA-4 blockade" has been published in the Journal for Immunotherapy of Cancer!


APRIL 2015

PUBLICATION: Thanks to the Sun Lab (UIC) for including us on the study "HIV Infection Leads to Redistribution of Leaky Claudin-2 in the Intestine of Humanized SCID IL-2R(-/-) Hu-PBMC Mice" published in AIDS Research and Human Retroviruses.



WE HAVE ARRIVED! I want to thank the administration at Rutgers Cancer Institute of New Jersey and the Department of Surgery at Rutgers Robert Wood Johnson Medical School for recruiting us here! Let a new phase in our discovery of mechanisms and cures for cancer begin!

THANK YOU! I want to thank my friends and colleagues in the Department of Internal Medicine and Department of Immunology/Microbiology at Rush University for a life-changing experience and for all the kind wishes on our move! -- we will miss seeing you all daily!


Toward this effort we utilize a double-humanized patient-derived xenograft model and novel biotechnologies that we have developed. These allow us to conduct in vivo studies of a patient’s anti-cancer immune response in the context of that patient’s intact tumor microenvironment, and to efficiently target our therapies to the tumor microenvironment. Our goals are to discover new cancer immunotherapies and to develop a unified theory of infection, cancer, and autoimmunity. 

Contact Us

We welcome inquiries about our research and new collaboration opportunities. Please contact us!

effective 3/6/17




precision medicine at Rutgers Cancer Institute




Donate Now








Proud member of
Big Ten Cancer Research Consortium



Rutgers Health